A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics AG CRSP shares rallied 9.6% in the last trading session to close at $60.08. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the ...

In this article, we will take a look at the Top 11 CRISPR Stocks to Invest in. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Pre-earnings options volume in Crispr Therapeutics (CRSP) is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move near 8.9%, or $4.56, after results are ...

Update: On 8 December, the US Food and Drug Administration approved the CRISPR–Cas 9 therapy for sickle cell disease described in this story. Less than a month after the world’s first approval of a ...

CRISPR pioneer Jennifer Doudna, Ph.D., looks set to continue to push the boundaries of gene editing, as she announces plans to team up with life sciences giant Danaher to create a center focused on ...

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...